Pre-Conference Day
Tuesday 24th June 2025
8:00 am Check In & Light Breakfast
8:55 am
Highlighting Clinical Updates of Neoantigen-Targeted Vaccines & Cell Therapies & Utilising Lessons Learnt to Facilitate Future Clinical Progression
9:00 am
WORKSHOP A
Identifying Rational, Synergistic Neoantigen Combination Strategies to Maximise Clinical Efficacy & Overcome Tumour Resistance to Improve Patient Response Rate
Synopsis
Helping the industry to overcome challenges in efficacy and tumour resistance, combination strategies have been hailed the future of immunotherapy, with neoantigen-targeted cell therapies and vaccines increasingly being administered alongside other immunotherapies. However, navigating the complexity of administering multiple drugs requires smart protocol design, identification of distinct biomarkers, careful monitoring of toxicity, and precise assays to elucidate the effect of each therapy.
This workshop will cover:
- Understanding the limitations of neoantigen monotherapies and identifying the most rational, synergistic combination strategies
- How to optimise patient selection based on individual patient and tumour characteristics and immunopeptidomic data
- How to schedule administration, determine dosing, and monitor toxicity in patients to maximise efficacy and tolerability of neoantigen-targeted therapy combinations
- Effectively monitoring immune response and identifying unique biomarkers to elucidate the effect of each individual therapy to determine synergy versus independent action
11:00 am Morning Break & Networking
11:30 am
WORKSHOP B
Eliciting the Desired Immune Response for Long Term Clinical Efficacy in Both Personalised & Off-The-Shelf Neoantigen Cancer Vaccines & Cell Therapies
Synopsis
When monitoring the effect of neoantigen therapies, it is important to understand whether observed immune responses will lead to tumour regression. Additionally, determining how targeted neoantigens are actually processed and presented on tumours is vital to ensure the most appropriate neoantigen targets are selected. Furthermore, selecting the right patients, indications, and conditioning regimen to maximise clinical success is necessary to increase the likelihood of an efficacious clinical response.
This workshop will address:
- Identifying an appropriate patient population based on patient and tumour characteristics to ensure the right patients are being treated at the right time
- Understanding at which line of treatment to administer neoantigen-based therapies, and which disease types are most responsive to treatment
- Selecting the right therapeutic platform and conditioning regimen for patients depending on their level of immune depletion to enhance therapeutic tolerability and achieve long-term efficacy
- Determining desired level of therapeutics efficacy and selecting appropriate read outs and end points to measure clinical success
1:30 pm Lunch Break & Networking
2:30 pm
WORKSHOP C
2:30 pm How Personalised Should Neoantigen-Targeted Cell Therapies & Cancer Vaccines Be? Unravelling the Limitations of Precision Neoantigen Therapies & Exploring Shared-Neoantigens for an Off-The-Shelf Approach
Synopsis
Personalised therapies hold promise to provide the most optimal treatment plan available to patients, overcoming tumour heterogeneity and resistance. However, identifying specific neoantigens and developing precision therapies incurs a high cost, complex logistical planning, and a lengthy timeframe which is often too great for patients with late-stage disease. As such, the feasibility and scalability of personalised therapies is uncertain.
Identifying shared neoantigens and developing off-the-shelf neoantigen therapies for small groups of patients could help overcome these challenges. Can allogenic therapies hold up against the precision of personalised therapies?
This workshop will delve into:
- The feasibility and scalability of personalised neoantigen therapies, considering the expense and logistics of manufacturing therapies for one person, the cost on patient health of delaying treatment, and health equity
- Identifying shared neoantigens and hotspot mutations in subsets of patients for the development of small-group off-the-shelf neoantigen vaccines and cell therapies
- Should neoantigen therapies be developed for individuals, small groups with shared neoantigens, or be truly off-the-shelf?